Overview

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Status:
Terminated
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
Female
Summary
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Bioepis Co., Ltd.
Treatments:
Trastuzumab
Criteria
Inclusion Criteria:

- Subjects who received the study treatment of SB3-G31-BC.

- Subjects who provide informed consent.

Exclusion Criteria:

- Subjects unwilling to follow the study requirements are not eligible for the study.